ArticleRisk analysis : an official publication of the Society for Risk Analysis2021
Assessing the Outbreak Risk of Epidemics Using Fuzzy Evidential Reasoning.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemic diseases (EDs) present a significant but challenging risk endangering public health, evidenced by the outbreak of COVID-19. Compared to other risks affecting public health such as flooding, EDs attract little attention in terms of risk assessment in the current literature. It does not well respond to the high practical demand for advanced techniques capable of tackling ED risks. To bridge this gap, an adapted fuzzy evidence reasoning method is proposed to realize the quantitative analysis of ED outbreak risk assessment (EDRA) with high uncertainty in risk data. The novelty of this article lies in (1) taking the lead to establish the outbreak risk evaluation system of epidemics covering the whole epidemic developing process, (2) combining quantitative and qualitative analysis in the fields of epidemic risk evaluation, (3) collecting substantial first-hand data by reviewing transaction data and interviewing the frontier experts and policymakers from Chinese Centers for Disease Control and Chinese National Medical Products Administration. This work provides useful insights for the regulatory bodies to (1) understand the risk levels of different EDs in a quantitative manner and (2) the sensitivity of different EDs to the identified risk factors for their effective control. For instance, in the case study, we use real data to disclose that influenza has the highest breakout risk level in Beijing. The proposed method also provides a potential tool for evaluating the outbreak risk of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.